Kindler is putting "Pfizer's full scope and scale" behind a push into the cancer market.
One Kindler, Elizabeth Glass, began an online petition, asking Amazon to fix the contrast.
"All you get is a plain brown envelope, " says Jeffrey Kindler, Pfizer's vice chairman.
But Kindler presented the board with a vision of how Pfizer could break with the past.
Mr Kindler also wants his secretive researchers to open up and work more closely with outsiders.
Mr Kindler joined Pfizer in 2002 as general counsel after holding a senior legal post at McDonald's.
Now Kindler says he is putting "Pfizer's full scope and scale" behind a push into the cancer market.
"Sometimes the best change agents are the people who are inside but not in a leadership position, " says Kindler.
Chief Executive Jeffrey Kindler has made one of his most important and much-awaited decisions: He reorganized his research labs.
Read is taking over for Jeffrey Kindler, who ran the company for four years and retired suddenly in November.
Kindler seems to be co-opting many of the best ideas of his rivals.
Last week Kindler picked Martin Mackay, who has been at Pfizer since 1995.
Kindler named an insider to run the labs, and no big successes resulted.
One of the biggest challenges Kindler faces is not merely operational but emotional.
"Despite our best efforts, Exubera has failed to gain the acceptance of patients and physicians, " Kindler said in a statement.
"There are a lot of patients that are suffering, and there's a tremendous opportunity to meet their needs, " Kindler says.
Mr Kindler acknowledges this, but says his experiences outside the firm showed that people like working without layers of bureaucracy.
Pfizer Chief Executive Jeffrey Kindler announced "an important decision" Thursday morning, in the press release that carried Pfizer's third-quarter financial results.
"I don't believe size for the sake of size is something to aspire to, " Kindler said in response to an analyst question.
Hillary Clinton, whose health plan the industry reviled a decade ago, is getting big pharma money, including from Pfizer Chairman Jeffrey Kindler.
In a surprise move, Pfizer announced that its top lawyer, JeffreyKindlerJeffrey Kindler, would replace Henry "Hank"McKinnellHenry "Hank" McKinnell as chief executive officer.
Instead, Kindler has gone with a more radical, and probably unprecedented, strategy.
This comes a week after Chairman and CEO Jeffrey Kindler left abrubtly.
FORBES: After Hours: Amgen's Drug May Help Patients Live Longer
Jeff Kindler gets to make the hard choice and kill the drug, but why was it still draining resources in the first place?
When it became clear in July 2006 that McKinnell's days were numbered, Kindler went to the board with plans to transform the company.
After six months, Pfizer Chief Executive Jeffrey Kindler has made one of his most important and much-awaited decisions: He reorganized his research labs.
Pfizer Chief Executive JeffreyKindlerJeffrey Kindler is making bold moves that seem to constitute a reversal of the strategies of his predecessor, HankMcKinnellHank McKinnell.
Many on Wall Street say Kindler's only option is to do what Pfizer has always done: buy somebody big, like Wyeth or Bristol-Myers Squibb.
"This is a risky business, and we all know that, " says Chief Executive Jeffrey Kindler, who's been in the job just over a year.
When Pfizer's then research chief John LaMattina suddenly announced his retirement in May, most people expected Kindler to nab an outsider to run the labs.
应用推荐